Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Allegra Ads Cited For Superiority Claims; Zyrtec Data Stronger, FDA Says

  • News

Executive Summary

FDA is challenging Aventis' TV and print advertisements for Allegra on the grounds that they imply the product is superior to other antihistamines, FDA's ad division said

You may also be interested in...



Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?

The antihistamine market can no longer comfortably be divided between prescription and OTC entrants, Aventis Chief Operating Officer Richard Markham suggested during the J.P. Morgan health care conference in San Francisco Jan. 13

Allegra “Drives On” With Physician Campaign Ahead Of Claritin OTC Switch

Aventis will not change its marketing strategy for Allegra following the departure of Schering-Plough's Claritin from the prescription antihistamine market

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS043155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By